Two Sigma Advisers
SYRE icon

Two Sigma Advisers’s Spyre Therapeutics SYRE Stock Holding History

Two Sigma Advisers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,432
Closed -$61.1K – 2652
2023
Q1 		$61.1K Sell
8,432
-2,480
-23% -$27.2K ﹤0.01% 2431
2022
Q4 		$123K Sell
10,912
-5,484
-33% -$98.6K ﹤0.01% 2273
2022
Q3 		$216K Buy
16,396
+7,128
+77% +$88.1K ﹤0.01% 2177
2022
Q2 		$117K Buy
9,268
+2,816
+44% +$98.7K ﹤0.01% 2374
2022
Q1 		$371K Buy
6,452
+4,924
+322% +$413K ﹤0.01% 2133
2021
Q4 		$181K Buy
+1,528
New +$241K ﹤0.01% 2306
2021
Q2 		– Sell
-1,352
Closed -$268K – 2686
2021
Q1 		$268K Sell
1,352
-1,184
-47% -$227K ﹤0.01% 2263
2020
Q4 		$499K Buy
2,536
+248
+11% +$51.4K ﹤0.01% 1866
2020
Q3 		$406K Buy
2,288
+580
+34% +$107K ﹤0.01% 1899
2020
Q2 		$395K Buy
1,708
+384
+29% +$73.1K ﹤0.01% 1998
2020
Q1 		$154K Buy
1,324
+8
+0.6% +$1.36K ﹤0.01% 2230
2019
Q4 		$251K Buy
1,316
+680
+107% +$133K ﹤0.01% 2115
2019
Q3 		$122K Buy
636
+84
+15% +$16.4K ﹤0.01% 2096
2019
Q2 		$95K Buy
+552
New +$95.4K ﹤0.01% 2217

Other funds holding SYRE

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Two Sigma Advisers's SYRE Position: Q2 2023 in Review

Two Sigma Advisers sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 8,432 shares — an estimated $61.1K sold.

Two Sigma Advisers first reported a position in SYRE in Q2 2019 and held it in 14 quarters. The position peaked at $499K in Q4 2020. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

  • Two Sigma Advisers reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 8,432 Spyre Therapeutics shares in Q2 2023, an estimated $61.1K.
  • Two Sigma Advisers first reported a position in Spyre Therapeutics in Q2 2019 and held it in 14 quarters.
  • Two Sigma Advisers's Spyre Therapeutics position peaked at $499K in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.